NCT07591727尚未招募1 期
Efficacy, Safety, and Feasibility of Metabolic ReConstruction Oral Biologics (Gut-X-001) in Patients With Alzheimer's Disease: An Exploratory Clinical Trial （ESCAPE-AD）
Beijing Tiantan Hospital0 个研究点目标入组 120 人开始时间: 2026年8月1日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
This is an exploratory clinical trial aimed at preliminarily evaluating the efficacy, safety, and feasibility of orally administered Gut-X-001 in patients with Alzheimer's disease (AD). An open-label extension (OLE) study will also be conducted to further investigate the effects of Gut-X-001. The study will assess the effects of Gut-X-001 on cognitive function, activities of daily living, neuroimaging indicators, and AD-related plasma biomarkers in AD patients. Safety will be systematically monitored, including the incidence of adverse events and changes in hematological and organ function parameters. Furthermore, the study will explore the regulatory effects of Gut-X-001 versus placebo on venous blood redox-related indicators and gut microbiota metabolite levels at different time points, providing a basis for multi-target intervention strategies and offering systematic evidence for the scientific rationale, feasibility, and safety of Gut-X-001 in the clinical management of AD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥50 and ≤85 years.
- •Diagnosis of Alzheimer's disease confirmed by a qualified neurologist based on the 2024 National Institute on Aging - Alzheimer's Association (NIA-AA) diagnostic criteria, with at least one abnormal core biomarker, including amyloid PET, CSF Aβ42/40, phosphorylated tau181 (p-tau181)/Aβ42, total tau (t-tau)/Aβ42, or plasma p-tau
- •MMSE score meeting the following criteria:
- •If years of education ≤6: MMSE score between 16 and 24 (inclusive); If years of education >6: MMSE score between 18 and 27 (inclusive).
- •Clinical Dementia Rating (CDR) global score of 0.5 (for MCI due to AD) or 1.0 (for mild AD dementia).
- •If receiving acetylcholinesterase inhibitor (AChEI) and/or memantine therapy, the dose must have been stable for at least 3 months prior to screening.
- •Participants must have a reliable caregiver who has frequent contact with the participant (at least 4 days per week and at least 2 hours per day). The caregiver must accompany the participant to all study visits, provide meaningful input for scale assessments through sufficient interaction with the participant, and remain consistent throughout the study period wherever possible.
- •The participant or their legally authorized representative is able and willing to provide written informed consent.
排除标准
- •Presence of other conditions that may contribute to cognitive impairment, including neurological disorders (e.g., vascular cognitive impairment, Parkinson's disease, frontotemporal dementia, Lewy body dementia) or psychiatric and affective disorders (e.g., severe anxiety/depression, schizophrenia).
- •Diagnosis of acute cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, myocardial infarction, or heart failure within the 3 months prior to screening.
- •Presence of other active or significant neurological conditions, including recurrent epileptic seizures, intracranial space-occupying tumors, vascular malformations (including arteriovenous malformations, arterial malformations, or cavernous malformations), or untreated aneurysms with a diameter >3 mm.
- •Severe hepatic impairment [ALT or AST >3× upper limit of normal (ULN), or concurrent acute hepatitis, chronic active hepatitis, or liver cirrhosis], renal impairment [estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m²], active malignancy, severe anemia, chronic obstructive pulmonary disease (COPD), immune system disorders, uncontrolled diabetes, or uncontrolled hypertension [systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg].
- •Currently receiving medications that may interfere with study outcomes.
- •Known hypersensitivity to the investigational drug or any of its excipients.
- •Formal education of 1 year or less.
- •Known history of severe organic disease or an anticipated survival of less than 12 months.
- •Pregnant or breastfeeding women, or women of childbearing potential who refuse to use contraceptive measures.
- •Participation in another clinical study within 30 days prior to screening, or currently enrolled in another clinical study.
- •Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment or unable to complete the study procedures and follow-up visits, such as psychiatric illness or physical conditions that preclude compliance with study requirements.
研究组 & 干预措施
Low-Dose Group
Experimental
Low-Dose Gut-X-001
干预措施: Gut-X-001 + Placebo capsule (Drug)
High-Dose Group
Experimental
High-Dose Gut-X-001
干预措施: Gut-X-001 (Drug)
Control Group
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
研究者
yilong Wang
Professor
Beijing Tiantan Hospital
相似试验
进行中（未招募）
4 期
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityChildhood ObesitySevere ObesityCardiovascular FunctionLiraglutideEchocardiographySpeckle TrackingNCT07590219University of Sao Paulo General Hospital30
尚未招募
2/3 期
Effect of Shigru (Moringa oleifera) Leaf Powder as an Add-on to Standard of Care in Metabolic SyndromeCTRI/2025/12/098814All India Institute of Medical Sciences Bhopal110
尚未招募
2/3 期
Treatment for Metabolic Syndrome by Panchakarma Therapy (Virechana) and Ayurvedic MedicineCTRI/2025/01/079134Ayurvedic and Unani Tibbia college and hospital40
尚未招募
不适用
A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese AdultsNCT07363148Arrae120
已完成
不适用
Metabolic Regeneration Registry for Periodontal Health (20-Patient Cohort).Chronic PeriodontitisChronic Periodontitis Wth Diabetes MellitusNon-surgical Periodontal TreatmentGingival RegenerationMetabolic RepairNCT07538661Amar h Zireg20